Lilly's Taltz and Zepbound show durable 52-week efficacy in PsO/PsA with obesity
Aug 31, 2026, 7:19 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive Phase 3b data showing durable efficacy in obesity-linked psoriatic diseases could lift near-term sentiment, with longer-term upside contingent on regulatory clearance and payer uptake.
AI summary
What happened, with direct paths to the underlying reporting
Lilly disclosed 52-week results from TOGETHER-PsO and TOGETHER-PsA, showing that Taltz and Zepbound together preserved or deepened improvements in skin and joint disease while improving systemic inflammation and metabolic markers in obese patients. The data are exploratory and open-label, but they underscore a potential immunometabolic treatment approach that could broaden Lilly's addressable market if validated in later trials and regulatory approval.
52-week data show Taltz+Zepbound sustain improvements vs Taltz alone.
Primary outcomes: PASI100+≥10% weight loss in PsO reached 30.6% vs 4.4%.
PsA: ACR50+≥10% weight loss at Week 52 reached 39.2% vs 1.7%.
Adverse events were mild/moderate; safety profile consistent with known data.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Eli Lilly has begun construction on a $3.5 billion injectable medicines manufacturing site in Lehigh Valley, Pennsylvania to add capacity for next-generation obesity treatments in…
The FDA requires safety-labeling changes for the GLP-1 receptor agonist drug class citing a potential increased risk of a rare but serious eye condition.
Eli Lilly's earnings release on Thursday morning is the near-term catalyst, with traders betting on a positive reaction that could lift LLY toward a fresh high. The market is focu…
A U.S. judge denied Novo Nordisk's request to stop Eli Lilly from advertising weight-loss drugs, allowing Lilly to maintain its marketing push. The decision preserves Lilly's near…